Bristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year results from the previously struggling pharma.
Almost half of cancer patients reported that their medical care team did not discuss clinical trials with them, and often discouraged participation when the subject was discussed, according
Bristol-Myers Squibb has withdrawn a European filing of its immunotherapy combination of Opdivo and Yervoy in first line lung cancer after a knock back from regulators, and plans a differen
California biotech Calibr and research partner AbbVie have clearance to start clinical trials of a new CAR-T technology, involving “switchable” cells that aim to eliminate the life-threaten
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
